• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺氧介导的HES4通过增强COL4A2转录促进肝癌细胞的增殖和运动。

Hypoxia-mediated HES4 promotes the proliferation and motility of hepatocellular carcinoma cell by enhancing COL4A2 transcription.

作者信息

Zhao Pingping, Xu Hong

机构信息

Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

出版信息

Discov Oncol. 2025 Jul 25;16(1):1405. doi: 10.1007/s12672-025-03152-4.

DOI:10.1007/s12672-025-03152-4
PMID:40715599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12297064/
Abstract

Hypoxia is a key feature of hepatocellular carcinoma (HCC) tissues. On one hand, it can drive HCC cell to alter their energy metabolism; on the other hand, it promotes the activation of multiple signaling pathways, thereby facilitating the progression of HCC. This study aims to explore the key hypoxia-driven genes and clarify their roles and molecular mechanisms. Through bioinformatics analysis of HCC tissues in the TCGA dataset, we identified 34 genes closely associated with hypoxia in HCC tissues. Among these 34 genes, we found that HES4 was highly expressed in HCC tissues and was associated with poor prognosis in patients. Using CCK-8, EdU assays, wound healing assays, and transwell assays, we demonstrated that knocking down HES4 significantly inhibited the proliferation and motility of HCC cell and notably alleviated hypoxia-induced enhancement of proliferation and motility. Mechanistically, we found that COL4A2 was highly expressed in HCC tissues with high HES4 expression and was positively correlated with HES4 expression. Furthermore, we discovered that HES4 could bind to the promoter of COL4A2 to promote its transcription. Overexpression of COL4A2 could reverse the effects mediated by HES4 silencing. Overall, this study revealed that hypoxia-mediated HES4 promotes the proliferation and motility of HCC cell by enhancing the transcription of COL4A2. HES4 was a key therapeutic target and biomarker in HCC.

摘要

缺氧是肝细胞癌(HCC)组织的一个关键特征。一方面,它可促使肝癌细胞改变其能量代谢;另一方面,它促进多种信号通路的激活,从而推动肝癌的进展。本研究旨在探索关键的缺氧驱动基因,并阐明其作用及分子机制。通过对TCGA数据集中肝癌组织进行生物信息学分析,我们鉴定出34个与肝癌组织缺氧密切相关的基因。在这34个基因中,我们发现HES4在肝癌组织中高表达,且与患者的不良预后相关。使用CCK-8、EdU检测、伤口愈合检测和Transwell检测,我们证明敲低HES4可显著抑制肝癌细胞的增殖和迁移,并明显减轻缺氧诱导的增殖和迁移增强。机制上,我们发现COL4A2在HES4高表达的肝癌组织中高表达,且与HES4表达呈正相关。此外,我们发现HES4可结合COL4A2的启动子以促进其转录。COL4A2的过表达可逆转HES4沉默介导的效应。总体而言,本研究揭示缺氧介导的HES4通过增强COL4A2的转录促进肝癌细胞的增殖和迁移。HES4是肝癌的关键治疗靶点和生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/b4d3b2d3fc89/12672_2025_3152_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/e238eb418065/12672_2025_3152_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/5a530e0bfc83/12672_2025_3152_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/a341ec64404e/12672_2025_3152_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/8a7e728a83ac/12672_2025_3152_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/07211932f50e/12672_2025_3152_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/b4d3b2d3fc89/12672_2025_3152_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/e238eb418065/12672_2025_3152_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/5a530e0bfc83/12672_2025_3152_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/a341ec64404e/12672_2025_3152_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/8a7e728a83ac/12672_2025_3152_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/07211932f50e/12672_2025_3152_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6dd/12297064/b4d3b2d3fc89/12672_2025_3152_Fig6_HTML.jpg

相似文献

1
Hypoxia-mediated HES4 promotes the proliferation and motility of hepatocellular carcinoma cell by enhancing COL4A2 transcription.缺氧介导的HES4通过增强COL4A2转录促进肝癌细胞的增殖和运动。
Discov Oncol. 2025 Jul 25;16(1):1405. doi: 10.1007/s12672-025-03152-4.
2
Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.核因子IA介导的晶状体蛋白αB转录调控抑制肝细胞癌进展。
Mol Clin Oncol. 2025 Jun 20;23(2):72. doi: 10.3892/mco.2025.2867. eCollection 2025 Aug.
3
Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma.在肝细胞癌中,长链非编码RNA ASH1L-AS1编码的微小蛋白APPLE通过抑制PP1/PP2A介导的ERK1/2去磷酸化对MAPK信号通路进行非经典激活。
J Exp Clin Cancer Res. 2025 Jul 11;44(1):200. doi: 10.1186/s13046-025-03465-w.
4
Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma.沉默NEDD4L可有效抑制肝癌的恶性行为。
J Hepatocell Carcinoma. 2025 Jul 10;12:1369-1391. doi: 10.2147/JHC.S511466. eCollection 2025.
5
Hepatitis B virus core/capsid protein induces hepatocellular carcinoma progression via long non-coding RNA KCNQ1OT1/miR-335-5p/CDC7 axis.乙型肝炎病毒核心/衣壳蛋白通过长链非编码RNA KCNQ1OT1/miR-335-5p/CDC7轴诱导肝细胞癌进展。
Transl Cancer Res. 2025 Jun 30;14(6):3319-3335. doi: 10.21037/tcr-2025-233. Epub 2025 Jun 16.
6
Disulfidptosis-related genes RPN1 inhibits the progression of hepatocellular carcinoma by regulating cell cycle, may be a new therapeutic targets.二硫键连接的细胞焦亡相关基因RPN1通过调控细胞周期抑制肝细胞癌进展,可能是新的治疗靶点。
Inflamm Res. 2025 Jul 22;74(1):105. doi: 10.1007/s00011-025-02070-z.
7
Bioinformatics analysis and experimental studies reveal KPNA2 as a novel biomarker of hepatocellular carcinoma progression and telomere maintenance.生物信息学分析和实验研究表明,核转运蛋白α2(KPNA2)是肝细胞癌进展和端粒维持的一种新型生物标志物。
Eur J Med Res. 2025 Jul 16;30(1):628. doi: 10.1186/s40001-025-02866-z.
8
Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma.七种缺氧和免疫相关特征预测肝细胞癌患者的预后
Dig Dis Sci. 2025 Jun 18. doi: 10.1007/s10620-025-09152-2.
9
Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis.整合素 αVβ1 激活的 PYK2 通过 STAT3-VGF 轴促进非小细胞肺癌的进展。
Cell Commun Signal. 2024 Jun 6;22(1):313. doi: 10.1186/s12964-024-01639-1.
10
PLAGL2 as a prognostic biomarker and an EMT-promoting factor in PDAC.PLAGL2作为胰腺癌的一种预后生物标志物和上皮-间质转化促进因子。
Sci Rep. 2025 Jul 14;15(1):25425. doi: 10.1038/s41598-025-09591-x.

本文引用的文献

1
Bestrophin-4 relays HES4 and interacts with TWIST1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells.Bestrophin-4传递HES4并与TWIST1相互作用,以抑制结肠癌细胞中的上皮-间质转化。
Elife. 2024 Dec 19;12:RP88879. doi: 10.7554/eLife.88879.
2
COL4A2 enhances thyroid cancer cell proliferation through the AKT pathway.COL4A2 通过 AKT 通路增强甲状腺癌细胞增殖。
Oncol Res. 2024 Aug 23;32(9):1467-1478. doi: 10.32604/or.2024.047382. eCollection 2024.
3
RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growth.
RNAi 筛选鉴定出 HES4 是一种调节氧化还原平衡的物质,支持嘧啶合成和肿瘤生长。
Nat Struct Mol Biol. 2024 Sep;31(9):1413-1425. doi: 10.1038/s41594-024-01309-3. Epub 2024 May 20.
4
Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors.整合公共数据集以发现和验证实体瘤中与生存相关的基因
Innovation (Camb). 2024 Apr 9;5(3):100625. doi: 10.1016/j.xinn.2024.100625. eCollection 2024 May 6.
5
The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.肝细胞癌中的细胞外基质:机制与治疗弱点。
Cell Rep Med. 2023 Sep 19;4(9):101170. doi: 10.1016/j.xcrm.2023.101170. Epub 2023 Aug 30.
6
Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development.缺氧诱导因子协调腺苷代谢促进肝癌发展。
Sci Adv. 2023 May 5;9(18):eade5111. doi: 10.1126/sciadv.ade5111.
7
Hypoxia-induced UBE2K promotes the malignant progression of HCC.缺氧诱导的UBE2K促进肝癌的恶性进展。
Pathol Res Pract. 2023 May;245:154422. doi: 10.1016/j.prp.2023.154422. Epub 2023 Mar 25.
8
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma.缺氧相关的环状PRDM4通过缺氧诱导因子-1α调控肝细胞癌中程序性死亡受体配体1促进免疫逃逸。
Exp Hematol Oncol. 2023 Feb 6;12(1):17. doi: 10.1186/s40164-023-00378-2.
9
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.肝细胞癌:分子机制、靶向治疗和生物标志物。
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.
10
Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities.肝细胞癌中的缺氧信号传导:挑战与治疗机遇
Cancer Metastasis Rev. 2023 Sep;42(3):741-764. doi: 10.1007/s10555-022-10071-1. Epub 2022 Dec 22.